Physician profile
Dakota Schmidt
NPI 1194329144
$5,007.69
in general payments reported to CMS, 2019-2025
32 companies · $26.81 in 2025
The $26.81 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,933 · 2022: $2,285 · 2023: $535 · 2024: $228 · 2025: $26.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.57 | 2021-2023 | |
| Novo Nordisk INC | $664.51 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $481.05 | 2021-2024 | Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $273.33 | 2021-2023 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $234.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $232.81 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Teva Pharmaceuticals USA, INC. | $219.42 | 2021-2023 | Ajovy |
| Amarin Pharma, INC. | $209.20 | 2021-2022 | |
| Pfizer INC. | $196.42 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.29 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.79 | 2021-2023 | Xifaxan |
| Scilex Pharmaceuticals INC. | $163.25 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $144.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.07 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $110.94 | 2024 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $99.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $84.89 | 2022-2023 | |
| Lundbeck LLC | $50.23 | 2022 | |
| Horizon Therapeutics Plc | $38.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.11 | 2022 | |
| Lockedbrands | $32.85 | 2024 | |
| Althera Pharmaceuticals LLC | $29.55 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $25.21 | 2022 | |
| Abbott Laboratories | $23.20 | 2022 | |
| Bausch Health US, LLC | $21.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.84 | 2022 | |
| Seqirus USA INC | $19.78 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.71 | 2022 | |
| Lilly USA, LLC | $18.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.29 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.85 | 2021 | |
| Vistapharm, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dakota Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.